GlaxoSmithKline Researchers Suppressed Data From China Tests of MS Drug
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
by Richard Daverman, PhD
July 23, 2013 -- Two years ago, an internal audit of practices at GlaxoSmithKline’s Shanghai R&D facility showed serious problems. Researchers did not report a total of six test results of a multiple sclerosis drug. By the time the tests were discovered, the drug, ozanezumab, was already being tested in humans. When GSK officials looked at the data, they stopped testing the drug in patients with MS, though trials for Lou Gherig’s disease were allowed to continue. The New York Times obtained a copy of the audit and broke the story, which was not previously known. More details....
Stock Symbol: (NYSE: GSK)
Help employers find you! Check out all the jobs and post your resume.
by Richard Daverman, PhD
July 23, 2013 -- Two years ago, an internal audit of practices at GlaxoSmithKline’s Shanghai R&D facility showed serious problems. Researchers did not report a total of six test results of a multiple sclerosis drug. By the time the tests were discovered, the drug, ozanezumab, was already being tested in humans. When GSK officials looked at the data, they stopped testing the drug in patients with MS, though trials for Lou Gherig’s disease were allowed to continue. The New York Times obtained a copy of the audit and broke the story, which was not previously known. More details....
Stock Symbol: (NYSE: GSK)
Help employers find you! Check out all the jobs and post your resume.